Latest Advances

  • Condition: Relapsed Primary Gastric Peripheral T-Cell Lymphoma
  • Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
  • Treatment Used: Total Gastrectomy followed by Add-on Chemotherapy
  • Number of Patients: 1
  • Published —
The study researched the safety and effectiveness of total gastrectomy followed by adjuvant chemotherapy for relapsed primary gastric peripheral T-cell lymphoma.
  • Condition: Esophageal Peripheral T-Cell Lymphoma
  • Journal: Medicine
  • Treatment Used: Radiotherapy
  • Number of Patients: 1
  • Published —
This case report describes a patient with esophageal peripheral T-cell lymphoma.
  • Condition: Peripheral T Cell Lymphoma
  • Journal: Journal of hematology & oncology
  • Treatment Used: Geptanolimab
  • Number of Patients: 102
  • Published —
In this study, researchers evaluated the safety and effectiveness of geptanolimab for the treatment of relapsed or refractory peripheral T cell lymphoma.
  • Condition: Subcutaneous Panniculitis-Like T-Cell Lymphoma with Hemophagocytic Lymphohistiocytosis Mimicking Cellulitis
  • Journal: The American journal of case reports
  • Treatment Used: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone, and Etoposide (ECHOP) Chemotherapy
  • Number of Patients: 1
  • Published —
This case report describes a patient with a rare form of subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic lymphohistiocytosis that mimicked cellulitis.
  • Condition: Relapsed or Refractory Peripheral T-cell Lymphomas
  • Journal: Annals of oncology : official journal of the European Society for Medical Oncology
  • Treatment Used: Copanlisib and Gemcitabine
  • Number of Patients: 28
  • Published —
The aim of this study was to evaluate the safety and effectiveness of copanlisib and gemcitabine in patients with relapsed/refractory peripheral T-cell lymphomas (PTCLs).
  • Condition: Peripheral T-Cell Lymphomas
  • Journal: Annals of hematology
  • Treatment Used: Busulfan, Etoposide, Cytarabine, and Melphalan
  • Number of Patients: 81
  • Published —
The study researched the outcomes of busulfan, etoposide, cytarabine, and melphalan for treating peripheral T-cell lymphomas.
  • Condition: Aggressive Adult T Cell Leukemia/Lymphoma
  • Journal: Scientific reports
  • Treatment Used: 5-aminolevulinic Acid-Mediated Photodynamic Therapy
  • Number of Patients: 13
  • Published —
The study researched the outcomes of 5-aminolevulinic acid-mediated photodynamic therapy for treating aggressive adult t cell leukemia/lymphoma.
  • Condition: Relapsed or Refractory Peripheral T-cell Lymphomas
  • Journal: F1000Research
  • Treatment Used: Salvage Chemotherapy and Stem Cell Transplantation
  • Number of Patients: 0
  • Published —
The study researched treatment outcomes of relapsed or refractory peripheral T-cell lymphomas.
  • Condition: Aggressive Adult T-cell Leukemia/lymphoma
  • Journal: Anticancer research
  • Treatment Used: Mogamulizumab Plus Chemotherapy
  • Number of Patients: 77
  • Published —
In this study, researchers evaluated the outcomes of treating aggressive adult T-cell leukemia/lymphoma with a combination of mogamulizumab and EPOCH chemotherapy.
  • Condition: B-cell Acute Lymphoblastic Leukemia (ALL) After Allogenic Stem Cell Transplantation
  • Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • Treatment Used: Maintenance Therapy Following CD19 CAR-T Treatment
  • Number of Patients: 1
  • Published —
This study evaluated maintenance therapy following an anti-CD19-CAR T-cell therapy for one B-cell acute lymphoblastic leukemia (ALL) patient who relapsed after allogeneic hematopoietic cell transplantation (allo-HSCT).
  • Condition: Peripheral T-Cell Lymphoma
  • Journal: Cancer medicine
  • Treatment Used: Interim Positron Emission Tomography-Computed Tomography (iPET/CT)
  • Number of Patients: 63
  • Published —
This study investigated the use of iPET/CT alongside baseline total lesion glycolysis measurements to predict clinical outcomes in patients with peripheral T-cell lymphoma.
  • Condition: Cutaneous T-Cell Lymphoma
  • Journal: European journal of cancer (Oxford, England : 1990)
  • Treatment Used: Brentuximab Vedotin
  • Number of Patients: 131
  • Published —
This study examined results from the randomized phase III ALCANZA study where adult patients with relapsed/ refractory cutaneous T-cell lymphoma were treated with brentuximab vedotin. Patient-reported quality of life (QoL), symptom burden, and peripheral neuropathy (PN) were assessed.
Showing 1-12 of 67